Drug intelligence / Profile preview

Virtuos Lyograft

Development stage: Unknown
Lead developer: Orthofix
Modality: Stem Cell Therapies → Cell Therapies
Administration: Surgical Implantation

Overview

Virtuos Lyograft is a shelf-stable cellular bone allograft developed by Orthofix Medical Inc. in partnership with MTF Biologics for use in spinal and orthopedic procedures. It is designed as a complete autograft substitute, providing the three essential components for bone healing: an osteoconductive scaffold, osteoinductive growth factors, and osteogenic cells (including mesenchymal stem cells and osteoprogenitor cells). The product utilizes a proprietary lyophilization (freeze-drying) process that allows for room-temperature storage while preserving the viability of the allogeneic cells. Upon hydration, the graft becomes a moldable material that can be easily implanted during surgery to promote bone fusion and repair.

Brand names: Virtuos Lyograft

Beyond the preview

Go deeper on Virtuos Lyograft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virtuos Lyograft.

Explore the full profile